Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Sophia Genetics SAS | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Pilot, prospective, mono-center study conducted in a population of healthy participants (free of cancer) for the analytical validation of circulating DNA analysis methods. The participants are employees of the institution. Their recruitement is carried out via internal posting (intranet and bulletin boards). The study participation will be strictly voluntary and without consequences on the professional situation of the participants.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Blood draw for analysis | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 1 single blood draw after in the inclusion of the participant in the study (Up to 30 mL). | Diagnostic Test | The samples will be processed by the laboratory as follows: - extraction of circulating DNA; - NGS Sequencing on 2 gene-panels; - capillary electrophoresis; - digital PCR |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of participants for which no pathogenic mutation has been detected on the MSK-Access panel. | Ratio of number of participants without pathogenic mutation on the MSK-Access panel over the total number of participants | baseline |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of participants for wich no pathogenic mutation has been detected on the HRR-Liq panel | Ratio of number of participants without pathogenic mutation on the HRR-Liq panel over the total number of participants | baseline |
| Proportion of participants for wich no pathogenic mutation has been detected on by digital PCR |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Laura KELLER, PhD | Contact | 0033 5 31 15 52 14 | keller.laura@iuct-oncopole.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institut Universitaire du Cancer de Toulouse - Oncopole | Recruiting | Toulouse | 31059 | France |
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Ratio of number of participants without pathogenic mutation via digital PCR panel over the total number of participants |
| baseline |
| Analytical specificity of the estimation of the circulating tumoral fraction: Proportion of participants for which the circulating tumoral fraction is inferior to the detectability threshold | Ratio of the number of participants for which the circulating tumoral fraction is inferior to the detectability threshold over the total number of participants | baseline |
| Analytical specificity of the measurement of circulating DNA fragments' size via electrophoresis: Proportion of participants with an absence of DNA fragments of a size inferior to 150 pb | Ratio of the number of participants for which there are no DNA fragments of a sieze inferior to 150 pb over the total number of participants | baseline |